Potency assays are central to proving a therapy activity and safety, yet for advanced therapies like cell and gene therapies they often require complex, bespoke solutions. Manufacturers face major ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...

While the use of cell therapies to treat hematological malignancies has been hailed as a clinical breakthrough, this promising new class of therapies has been far less effective in treating solid ...

HOUSTON, Dec. 3, 2025 /PRNewswire/ -- Avance Biosciences today announced the opening of its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and ...

A naturally occurring mutation in T cells that leads to lymphoma can be weaponized to make engineered T-cell therapies more effective against cancer, including melanoma, findings from a new study in ...

Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived ...

CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP ...

MIAMI - Longeveron Inc. (NASDAQ:LGVN) announced Thursday that the Japan Patent Office has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs). The ...

Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...